查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495442

消化不良藥物市場：按類型、藥物類型、分銷管道分類 - 全球預測 2024-2030

Dyspepsia Drug Market by Type (Functional Dyspepsia, Organic Dyspepsia), Drug Type (Acid Reducer, Antacids, Antibiotics), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

消化不良治療市場規模預計2023年為85.8億美元，預計2024年將達到90.1億美元，2030年將達到121.8億美元，複合年成長率為5.12%。

消化不良藥物市場包括所有用於治療慢性或復發性上腹部疼痛、不適、腹脹和噁心（俗稱消化不良）的藥物。由於飲食、壓力、老化等原因，世界上消化不良的發病率不斷增加，這大大增加了對有效治療解決方案的需求。胃腸道藥物治療研究的改進導致了更有效、起效更快的藥物的開發，改善了患者的治療效果。加強醫療基礎設施和提高人們對治療選擇的認知也推動了市場的成長。然而，長期使用某些消化不良藥物（例如質子幫浦阻斷劑（PPI））相關的潛在副作用可能會阻礙其使用並影響市場成長。開發新藥需要大量投資，並且存在臨床試驗失敗的風險，這對市場進入和技術創新造成了重大障礙。此外，人們對可以解決多種病症並提供綜合治療方法、提高患者依從性和治療結果的聯合治療越來越感興趣。遺傳和分子譜分析的進步可能會帶來更個人化的治療方法，從而最佳化治療效果並最大限度地減少副作用。

主要市場統計
基準年[2023] 85.8億美元
預測年份 [2024] 90.1億美元
預測年份 [2030] 121.8億美元
複合年成長率（%） 5.12%

區域洞察

在美洲地區，製藥和醫療保健產業隨著消化不良治療的持續創新和研究而不斷發展。美洲市場的特點是嚴格監管，確保提供有效和安全的治療方法。加拿大提供先進的醫療保健，我們對藥物核准採取預防措施，確保投放市場的藥物經過嚴格審查。歐洲國家受益於歐洲藥品管理局 (EMA) 的全面監管，簡化了醫藥品認證過程。生活方式的改變和老年人口的增加導致該地區消化不良治療的需求不斷成長。中東地區醫療保健支出的增加和對胃腸道疾病的認知不斷提高，促進了市場的成長。非洲地區更注重可近性和可負擔性，政府採取措施努力讓更多人更容易獲得治療。亞太地區消化不良的盛行率顯著增加，主要是由於飲食變化和壓力水平增加。中國、日本和印度等國家正大力投資醫療基礎設施和研究，以解決醫療保健問題。印度和中國人口眾多，代表著多元化的市場，對胃腸道問題的非處方藥和處方箋治療的認知和需求不斷成長。日本人口老化青睞高品質、精確配方的胃腸道疾病治療，這是市場成長的重要動力。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在消化不良治療藥物市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對消化不良治療市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該領域競爭性質的寶貴見解，包括累積研究期、片段化優勢和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對他們目前在消化不良治療市場中的地位進行全面評估將有助於公司做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球消化不良盛行率飆升
      • 支持加速藥品核准流程的政府政策
      • 投資改良藥物輸送和包裝技術
    • 抑制因素
      • 產品召回與安全問題
    • 機會
      • 透過聯合開發和公私合營進行擴張
      • 提高藥物療效的研發進展
    • 任務
      • 假藥的可用性
  • 市場區隔分析
    • 類型：功能性消化不良的廣泛發生和轉向更個性化的藥物
    • 藥物類型：擴大使用質子幫浦阻斷劑和H2受體阻斷劑來治療消化不良
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章消化不良治療藥物市場：依類型

  • 功能性消化不良
  • 器質性消化不良

第7章消化不良治療藥物市場（按類型）

  • 抑酸劑
  • 制酸劑
  • 抗生素
  • 抗驚厥藥
  • 抗憂鬱症
  • 西咪替丁
  • 法莫替丁
  • H2拮抗劑
  • 尼扎替丁
  • 消化促進劑
  • 質子幫浦抑制劑
  • Rabeprazole
  • 贊塔克

第8章消化不良治療藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章北美及南美消化不良藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太消化不良治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲/中東/非洲消化不良藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 突破性 FDA核准，Fathom Pharmaceuticals 宣布糜爛性胃食道逆流症治療藥物 VOQUEZNA
    • 剪切機-Smith推出法莫替丁口服混懸劑是美國學名藥市場的策略性舉措。
    • Mark Sands Pharma非專利藥法莫替丁錠獲得美國FDA核准
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-5D693B46BAC4

[193 Pages Report] The Dyspepsia Drug Market size was estimated at USD 8.58 billion in 2023 and expected to reach USD 9.01 billion in 2024, at a CAGR 5.12% to reach USD 12.18 billion by 2030.

The dyspepsia drug market includes all pharmaceuticals used in the treatment of dyspepsia, commonly known as indigestion, identified by chronic or recurrent pain in the upper abdomen, a feeling of discomfort, bloating, and nausea, which may or may not be related to meals. Rising global incidences of dyspepsia, driven by dietary habits, stress, and the aging population, significantly contribute to the demand for effective treatment solutions. Improved research in gastrointestinal pharmacotherapy has led to the development of more effective and faster-acting drugs, enhancing patient outcomes. Enhanced healthcare infrastructure, along with growing awareness of treatment options among populations, boosts the market growth. However, potential adverse effects associated with long-term use of certain dyspepsia drugs, such as Proton-pump inhibitor (PPIs), can deter their usage and affect market growth. Significant investment required for new drug development and risk of failure in clinical trials are major barriers to entry and innovation in the market. Moreover, growing interest in exploring combination therapies that can address multiple symptoms or provide a comprehensive treatment regimen, thus improving patient adherence and outcomes. Advances in genetic and molecular profiling can lead to more personalized treatment approaches, optimizing therapeutic effectiveness and minimizing side effects.

KEY MARKET STATISTICS
Base Year [2023] USD 8.58 billion
Estimated Year [2024] USD 9.01 billion
Forecast Year [2030] USD 12.18 billion
CAGR (%) 5.12%

Regional Insights

In the Americas region, pharmaceutical and healthcare sectors are advancing with ongoing innovations and research in dyspepsia drugs. The Americas market is characterized by strong regulations, which ensure the availability of effective and safe treatments. Canada offers a sophisticated healthcare landscape with a more precautionary approach towards drug approval which ensures drugs entering the market are highly vetted. European countries benefit from collective regulations under the European Medicines Agency (EMA), which streamlines drug approval processes. Lifestyle changes and an increasing elderly population contribute to the growing need for dyspepsia drugs in the region. The Middle East region shows increasing healthcare expenditure and growing awareness about gastrointestinal diseases, contributing to the market growth. The African region is more focused on accessibility and affordability, with efforts aimed at making treatments available to a more significant portion of the population through governmental initiatives. The Asia Pacific region observed a significant surge in the prevalence of dyspepsia, primarily due to changes in dietary habits and increasing stress levels. Countries such as China, Japan, and India are heavily investing in healthcare infrastructure and research to address healthcare issues. With vast populations, India and China present a diverse market with increasing awareness and demand for over-the-counter and prescription treatments for gastrointestinal issues. Japan's aging population is a notable factor contributing to the market growth, observing a preference for high-quality and precisely formulated dyspepsia medications.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Dyspepsia Drug Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Surging prevalence of Dyspepsia worldwide
      • Government policies favoring faster drug approval processes
      • Investment in improved drug delivery and packaging technologies
    • Market Restraints
      • Product recall and safety concerns
    • Market Opportunities
      • Expansion through collaborative development and public-private partnerships
      • Advancements in research and development for enhanced drug efficacy
    • Market Challenges
      • Availability of the counterfeit drugs
  • Market Segmentation Analysis
    • Type: Wide occurrence of functional dyspepsia with the shift towards more personalized drugs
    • Drug Type: Growing utilization of proton pump inhibitors and H2 receptor blockers for dyspepsia treatment
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Dyspepsia Drug Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Dyspepsia Drug Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Breakthrough FDA Approval, Phathom Pharmaceuticals Unveils VOQUEZNA for Erosive GERD Treatment

Phathom Pharmaceuticals Inc., specializing in GI disease solutions, has received FDA approval for VOQUEZNA (vonoprazan) in both 10 mg and 20 mg tablets, introducing a significant advancement in the treatment of Erosive GERD for adults. This development provides a fresh treatment option for the roughly 20 million Americans suffering from this severe form of acid reflux, addressing a critical need unmet by existing therapies. [Published On: 2023-11-01]

Launch of Upsher-Smith's Famotidine for Oral Suspension, A Strategic Move in the U.S. Generic Drug Market

Upsher-Smith Laboratories, LLC, in collaboration with Appco Pharma LLC, has introduced Famotidine for Oral Suspension, USP to the U.S. market. Upsher-Smith, renowned for its commitment to quality and consistent supply, offers this FDA-approved medication to provide an alternative treatment for conditions addressed by famotidine. [Published On: 2023-08-16]

Marksans Pharma Secures USFDA Approval for Generic Famotidine Tablets

Marksans Pharma Ltd. has announced receiving the final approval from the U.S. Food and Drug Administration (USFDA) for its generic Famotidine tablets, used in treating acid indigestion and heartburn. The company intends to expand its over-the-counter gastrointestinal portfolio with this product, addressing a significant therapeutic need that emerged following the withdrawal of Ranitidine to better serve customers and fill a vital market gap in antacid therapies. [Published On: 2023-03-10]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Dyspepsia Drug Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Dyspepsia Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ANI Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Cadila Pharmaceuticals, Dr Reddy's Laboratories Ltd, Haleon PLC, Intas Pharmaceuticals Ltd., Lupin Ltd., Mankind Pharma, Pfizer Inc., Prestige Consumer Healthcare Inc., Procter & Gamble Company, Salix Pharmaceuticals, Inc. by Valeant Pharmaceuticals International, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., and Torrent Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Dyspepsia Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Functional Dyspepsia
    • Organic Dyspepsia
  • Drug Type
    • Acid Reducer
    • Antacids
    • Antibiotics
    • Anticonvulsant
    • Antidepressants
    • Cimetidine
    • Famotidine
    • H2 Antagonist
    • Nizatidine
    • Prokinetic agent
    • Proton-pump Inhibitor
    • Rabeprazole
    • Zantac
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of Dyspepsia worldwide
      • 5.1.1.2. Government policies favoring faster drug approval processes
      • 5.1.1.3. Investment in improved drug delivery and packaging technologies
    • 5.1.2. Restraints
      • 5.1.2.1. Product recall and safety concerns
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion through collaborative development and public-private partnerships
      • 5.1.3.2. Advancements in research and development for enhanced drug efficacy
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of the counterfeit drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Wide occurrence of functional dyspepsia with the shift towards more personalized drugs
    • 5.2.2. Drug Type: Growing utilization of proton pump inhibitors and H2 receptor blockers for dyspepsia treatment
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Dyspepsia Drug Market, by Type

  • 6.1. Introduction
  • 6.2. Functional Dyspepsia
  • 6.3. Organic Dyspepsia

7. Dyspepsia Drug Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Acid Reducer
  • 7.3. Antacids
  • 7.4. Antibiotics
  • 7.5. Anticonvulsant
  • 7.6. Antidepressants
  • 7.7. Cimetidine
  • 7.8. Famotidine
  • 7.9. H2 Antagonist
  • 7.10. Nizatidine
  • 7.11. Prokinetic agent
  • 7.12. Proton-pump Inhibitor
  • 7.13. Rabeprazole
  • 7.14. Zantac

8. Dyspepsia Drug Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Dyspepsia Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Dyspepsia Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Dyspepsia Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Breakthrough FDA Approval, Phathom Pharmaceuticals Unveils VOQUEZNA for Erosive GERD Treatment
    • 12.3.2. Launch of Upsher-Smith's Famotidine for Oral Suspension, A Strategic Move in the U.S. Generic Drug Market
    • 12.3.3. Marksans Pharma Secures USFDA Approval for Generic Famotidine Tablets
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DYSPEPSIA DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. DYSPEPSIA DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DYSPEPSIA DRUG MARKET DYNAMICS
  • FIGURE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. DYSPEPSIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. DYSPEPSIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DYSPEPSIA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FUNCTIONAL DYSPEPSIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FUNCTIONAL DYSPEPSIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORGANIC DYSPEPSIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORGANIC DYSPEPSIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ACID REDUCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ACID REDUCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTACIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTICONVULSANT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTICONVULSANT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY CIMETIDINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FAMOTIDINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY H2 ANTAGONIST, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY H2 ANTAGONIST, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY NIZATIDINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROKINETIC AGENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROKINETIC AGENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROTON-PUMP INHIBITOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROTON-PUMP INHIBITOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ZANTAC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ZANTAC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. CHINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. CHINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. INDIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. INDIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 120. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 121. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 132. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 144. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 156. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 157. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 162. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 163. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 168. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 177. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 206. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 207. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. ITALY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. ITALY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 218. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 219. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 230. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 231. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. POLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. POLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 242. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 243. QATAR DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. QATAR DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 254. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 255. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 266. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 267. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 278. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 279. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 290. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 291. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 302. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 303. DYSPEPSIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 304. DYSPEPSIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023